Formulations of creatine and cyclodextrin exhibiting improved bioavailability
US12280067B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2019 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Jan 11, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulations of creatine, preferably phosphocreatine and most preferably disodium phosphocreatine, combined with cyclodextrin exhibit improved uptake across digestive mucosa, including intestinal, esophageal, and stomach mucosa. In particular, the formulations of the present invention are designed for protection of the cyclodextrin as it comes in contact with gastric juices so as to allow thereafter for unexpectedly improved site-specific intestinal release.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.